Treatment of behavioural disturbances in Parkinson's disease

Journal of Neural Transmission, Supplement

Volumn , Issue 51, 1997, Pages 175-204

  Valldeoriola, F ^a   Nobbe, F A ^a   Tolosa, E ^a,b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIPARKINSON AGENT; ANXIOLYTIC AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; LONG ACTING DRUG; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; ONDANSETRON; REMOXIPRIDE; RISPERIDONE; SELEGILINE; SEROTONIN ANTAGONIST; SEROTONIN UPTAKE INHIBITOR; TERGURIDE;

ANXIETY; BEHAVIOR DISORDER; COGNITIVE DEFECT; CONFERENCE PAPER; DEPRESSION; DREAMING; EXTRAPYRAMIDAL SYMPTOM; HUMAN; MOTOR DYSFUNCTION; NIGHTMARE; PARKINSON DISEASE; PRIORITY JOURNAL; PSYCHOSIS; SLEEP DISORDER; AGED; MENTAL DISEASE; MIDDLE AGED; PSYCHOLOGICAL ASPECT; REVIEW;

AGED; ANTIPARKINSON AGENTS; HUMANS; MENTAL DISORDERS; MIDDLE AGED; PARKINSON DISEASE;

EID: 0031283222     PISSN: 03036995     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-7091-6846-2_15     Document Type: Conference Paper

References (194)

1. Albert ML, Feldman RG, Willis A (1974) The "subcortical dementia" of progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 37: 121-130
2. Algeri S, De Luigi A, De Simoni MG, et al (1988) Multiple and complex effects of buspirone on central dopaminergic system. Psychopharmacol Biochem Behav 29: 823-826
3. Akai T, Yamaguchi M, Mizuta E, Kuno S (1993) Effects of terguride, a partial D2 agonist, on MPTP-lesioned parkinsonian cynomolgus monkeys. Ann Neurol 33: 507-511
4. American Psychiatric Association, Committee of Nomenclature and Statistics (1987) Diagnostic and statistical manual of mental disorders, 3rd edn, rev. American Psychiatric Association, Washington DC
5. Anderson GD, Rebec GV (1988) Clozapine and haloperidol in the amygdaloid complex: differential effects on dopamine transmission with long-term treatment. Biol Psychiatry 23: 497-506
6. Andrade R, Nicoll RA (1987) Novel anxyolitics discriminate between postsynaptic serotonin receptors mediating different physiological responses on single neurons of the rat hippocampus. Arch Pharmacol 336: 5-10
7. Baldessarini RJ, Frankenburg FR (1991) Clozapine, a novel antipsychotic drug. N Engl J Med 324: 746-754
8. Baldessarini RJ, Marsh ER, Kula NS (1992) Interactions of fluoxetine with metabolism of dopamine and serotonin in rat brain regions. Brain Res 579: 152-156
9. Barbeau A (1969) L-dopa therapy in Parkinson's disease: a critical review of nine years' experience. J Can Med Assoc 101: 791-800
10. Baxter LR, Schwartz JM, Phelps ME, et al (1989) Reduction of prefrontal glucose metabolism common to three types of depression. Arch Gen Psychiatry 46: 243-250
11. Beardsley JV, Puletti F (1971) Personality (MMPI) and cognitive (WAIS) changes after levodopa treatment: occurrence in patients with Parkinson's disease. Arch Neurol 25: 145-150
12. Beasley BL, Nutt JG, Davenport RW, Chase TN (1980) Treatment with tryptophan of levodopa associated psychiatric disturbances. Arch Neurol 37: 155-156
13. Beck AT, Ward CH, Mandelson M, Mock M, Erbaugh J (1961) An inventory for measuring depression. Arch Gen Psychiatry 4: 561-571
14. Biggins CA, Boyd JL, Harrop FM, Medeley P, Mindham RHS, Randall JI, Spokes EGS (1992) A controlled, longitudinal study of dementia in Parkinson's disease. J Neurol Neurosurg Psychiatry 55: 566-571
15. Borison RL (1995) Clinical efficacy of serotonin-dopamine antagonists relative to classic neuroleptics. J Clin Psychopharmacol 15 [Suppl 1]: 24-29
16. Borison RL, Fields JZ, Diamond BL (1981) Site-specific blockade of dopamine receptors by neuroleptic agents in human brain. Neuropharmacol 20: 1321-1322
17. Borison RL, Rathiraja AP, Bruce I, et al (1992) Risperidone: clinical safety and efficacy in schizophrenia. Psychopharmacol Bull 28: 213-218
18. Bouchard RH, Pourcher E, Vincent P (1989) Fluoxetine and extrapyramidal side-effects. Am J Psychiatry 46: 1352-1253
19. Bowen FP, Kamienny RS, Burns MM, Yahr MD (1975) Parkinsonism: effect of levodopa treatment on concept formation. Neurology 25: 701-704
20. Brown R, Marsden CD (1986) Visuospatial function in Parkinson's disease. Brain 109: 987-1002
21. Brown R, Jahnshahi M (1995) Depression in Parkinson's disease: a psychosocial viewpoint. In: Weiner WG, Lang AE (eds) Advances in neurology, vol 65. Behavioural neurology of movement disorders. Raven Press, New York, pp 61-84
22. Bürki HR, Eichenberger E, Sayers AC, White TG (1975) Clozapine and the dopamine hypothesis of schizophrenia, a critical appraisal. Pharmakopsychiatr Neuropsychopharmakol 8: 115-121
23. Caparros-Lefebvre D, Pécheux N, Petit V, Duhamel A, Petit H (1995) Which factors predict cognitive decline in Parkinson's disease. J Neurol Neurosurg Psychiatry 58: 51-55
24. Celesia GG, Wanamaker WM (1972) Psychiatric disturbances in Parkinson's disease. Dis Nerv Syst 33: 577-583
25. Ceulemans DLS, Gelders YG, Hoppenbrouwers ML, Reyntjens AJ, Janssen PAJ (1985) Effects of serotonin antagonists on schizophrenia: a pilot study with setoperone. Psychopharmacol 85: 329-332
26. Cheng AVT, Ferrier IN, Morris CM, et al (1991) Cortical serotonin-S2 receptor binding in Lewy body dementia, Alzheimer's and Parkinson's diseases. J Neurol Sci 106: 50-55
27. Chinaglia G, Landwehrmeyer B, Probst A, Palacios JM (1993) Serotoninergic terminal transporters are differentially affected in Parkinson's disease and progressive supranuclear palsy: an autoradiographic study with (3H)citalopram. Neuroscience 54: 691-699
28. Chouinard G, Jones B, Remington G, et al (1993) Canadian multi-centre placebo controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 13: 25-40
29. Cianchetti C (1985) Dopamine agonists and sleep in man. In: Wauquier A, Gaillard JM, Monti JM, Radulovacki M (eds) Sleep: neurotransmitters and neuromodulators. Raven Press, New York, pp 121-134
30. Claus A, Bollen J, De Cuyper H, et al (1992) Risperidone versus haloperidol in the treatment of chronic schizophrenic in-patients: a multi-centre, double-blind comparative study. Acta Psychiatr Scand 85: 295-305
31. Cohen BM, Herschel M, Aoba A (1979) Neuroleptic antimuscarinic and antiadrenergic activity of chlorpromazine, thioridazine and their metabolites. Psychiatry Res 1: 199-208
32. Cohen S, Chiles J, McNaughton A (1990) Weight gain associated with clozapine. Am J Psychiatry 147: 503-504
33. Cooper JA, Sagar HJ (1993) Incidental and intentional recall in Parkinson's disease: an account based on diminished attentional resources. J Clin Exp Neuropsychol 15: 713-731
34. Cooper JA, Sagar HJ, Doherty SM, et al (1992) Different effects of dopaminergic and anticholinergic therapy on memory performance in Parkinson's disease. Brain 115: 1701-1725
35. Cowen PJ (1993) Serotonin receptor subtypes in depression: evidence from studies in neuroendocrine regulation. Clin Neuropharmacol 16 [Suppl 3]: 6-18
36. D'Amato RJ, Zweig RM, Whitehouse PJ, et al (1987) Aminergic systems in Alzheimer's disease and Parkinson's disease. Ann Neurol 22: 229-236
37. De Vos RA, Jansen EN, Stam FC, Ravid R, Swab DF (1995) "Lewy body disease": clinico-pathological correlations in 18 consecutive cases of Parkinson's disease with and without dementia. Clin Neurol Neurosurg 97: 12-22
38. Dogali M, Fazzini E, Kolodny E, et al (1995) Stereotactic ventral pallidotomy for Parkinson's disease. Neurology 45: 753-761
39. Dogali M, Sterio D, Fazzini E, et al (1996) Effects of posteroventral pallidotomy in Parkinson's disease. In: Battistin L, Scarlato G, Caraceni T, Ruggieri S (eds) Advances in neurology, vol 69. Parkinson's disease. Lippincot-Raven, Philadelphia, pp 585-590
40. Donelli EF, Chase TN (1972) Intellectual and memory function in parkinsonian and non-parkinsonian patients treated with 1-dopa. Dis Nerv Syst 34: 119-123
41. Dubois B, Danze F, Pilon B, et al (1987) Cholinergic-dependent deficits in Parkinson's disease. Ann Neurol 22: 26-30
42. Duncombe ME, Bradshaw JL, Iansek R, Phillips JG (1994) Parkinsonian patients without dementia or depression do not suffer from bradyphrenia as indexed by performance in mental rotation tasks with and without advance information. Neuropsychologia 32: 1383-1396
43. Eison AS, Eison MS, Torrente JR, Wright RN, Yocca FD (1990) Nefazodone: preclinical pharmacology of a new antidepressant. Psychopharmacol Bull 26: 311-315
44. Factor SA, Brown D (1992) Clozapine prevents recurrence of psychosis in Parkinson's disease. Mov Disord 7: 125-131
45. Factor SA, McAlarney T, Sánchez-Ramos JR, Weiner WJ (1990) Sleep disorders and sleep effect in Parkinson's disease. Mov Disord 5: 280-285
46. Factor SA, Brown D, Molho ES, Podskalny GD (1994) Clozapine: a 2-year open trial in Parkinson's disease patients with psychosis. Neurology 44: 544-546
47. Factor SA, Molho ES, Podskalny GD, Brown D (1995) Parkinson's disease: drug-induced psychiatric states. In: Weiner WJ, Lang AE (eds) Advances in neurology, vol 65. Raven Press, New York, pp 115-138
48. Fahn S, Libsch LR, Cutler RW (1971) Monoamines in the human neostriatum: topographic distribution in normals and in Parkinson's disease in their role in akinesia, rigidity, chorea and tremor. J Neurol Sci 14: 427-455
49. Farde L, Nordström A-L (1992) PET analysis indicates typical central dopamine receptor occupancy in clozapine-treated patients. Br J Psychiatry 160 [Suppl 17]: 30-33
50. Farde L, Wiesel FA, Nordström A-L, Sedvall G (1989) D1- and D2-dopamine receptor occupancy during treatment with conventional and atypical neuroleptics. Psychopharmacol 99: 28-31
51. Farina E, Cappa SF, Polimeni M, Magni E, Canesi M, Zechinelli A, Scarlato G, Mariani C (1994) Frontal dysfunction in early Parkinson's disease. Acta Neurol Scand 90: 34-38
52. Feighner JP, Pambakian R, Fowler RC, et al (1989) A comparison of nefazodone, imipramine and placebo in patients with severe to moderate depression. Psychopharmacol Bull 25: 219-221
53. Feighner JP, Boyer WF, Tyler DL, Neborsky RJ (1990) Adverse consequences of fluoxetine-MAOI combination therapy. J Clin Psychiatry 51: 222-225
54. Folstein MF, Folstein SE, McHugh PR (1975) "Mini-Mental State", a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12: 189-198
55. Fontaine R (1993) Novel serotonergic mechanisms and clinical experience with nefazodone. Clin Neuropharmacol 16 [Suppl 3]: 45-50
56. Ford B, Lynch T, Greene P (1994) Risperidone in Parkinson's disease. Lancet 344: 681
57. Fram D, Murphy D, Goodwin F, et al (1970) L-Dopa and sleep in depressed patients. Psychophysiology 7: 316-317
58. Friedman JH (1991) The management of the levodopa psychoses. Clin Neuropharmacol 14: 283-295
59. Friedman JH, Lannon MC (1989) Clozapine in the treatment of psychosis in Parkinson's disease. Neurology 39: 1219-1221
60. Fungfeld EW, Baggen M, Nedwidek P, et al (1989) Double blind study with phosphatidylserine in parkinsonian patients with senile dementia of Alzheimer's type (SDAT). Prog Clin Biol Res 317: 1235-1246
61. Gedye A (1991) Buspirone alone or with serotonergic diet reduced aggression in a developmentally disabled adult. Biol Psychiatry 30: 88-91
62. Gerlach J, Peacock L (1994) Motor and mental side-effects of clozapine. J Clin Psychiatry 55 S B: S107-S109
63. German DC, Menaye K, Smith WK, Woodward DJ, Saper CB (1989) Midbrain dopaminergic cell loss in Parkinson's disease: computer visualization. Ann Neurol 26: 507-514
64. Gerson SL (1993) Clozapine- deciphering the risks. N Engl J Med 329: 204-205
65. Goetz CG, Stebbins GT (1993) Risk factors for nursing home placement in advanced Parkinson's disease. Neurology 43: 2227-2229
66. Gómez Arévalo G, Gershanik OS (1993) Modulatory effect of clozapine on levodopa response in Parkinson's disease: a preliminary study. Mov Disord 8: 349-354
67. Goodwin FK (1971) Psychiatric side-effects of levodopa in man. JAMA 218: 1915-1920
68. Gotham AM, Brown RG, Marsden CD (1986) Depression in Parkinson's disease: a quantitative and qualitative analysis. J Neurol Neurosurg Psychiatry 49: 381-389
69. Gross G, Xin X, Gastpar M (1991) Trimipramine: pharmacological reevaluation and comparison with clozapine. Neuropharmacol 30: 1159-1166
70. Haring C, Neudorfer C, Schwitzer J, et al (1994) EEG alterations in patients treated with clozapine in relation to plasma levels. Psychopharmacol 114: 97-100
71. Halgin R, Riklin M, Misiak H (1977) Levodopa, parkinsonism, and recent memory. J Nerv Ment Dis 164: 268-272
72. Halliday GM, Blumbergs PC, Cotton RGH, et al (1990) Loss of brainstem serotonin- and substance P- containing neurons in Parkinson's disease. Brain Res 510: 104-107
73. Halperin JR, Murphy B (1992) Extrapyramidal reaction to ondansetron. Cancer 69: 1275
74. Hamilton M (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry 23: 56-62
75. Harnel AR, Riklan M (1975) Cognitive and perceptual effects of long range 1-dopa therapy in parkinsonism. J Clin Psychol 31: 321-333
76. Heinrich K, Klieser E, Lehmann E, Kinzler E (1991) Experimental comparison of the efficacy and compatibility of risperidone and clozapine in acute schizophrenia. In: Kane JM (ed) Risperidone: major progress in antipsychotic treatment. Oxford Clinical Communications, Oxford, pp 37-39
77. Hietanen M, Teräväinen H (1988) The effect of age of disease onset on neuropsychological performance in Parkinson's disease. J Neurol Neurosurg Psychiatry 51: 244-249
78. Huber SJ, Shulman HG, Paulson GW, Shuttleworth EC (1987) Fluctuations in plasma dopamine level impair memory in Parkinson's disease. Neurology 37: 1371-1375
79. Huber SJ, Shulman HG, Paulson GW, Shuttleworth EC (1989) Dose-dependent memory impairment in Parkinson's disease. Neurology 39: 438-440
80. Hughes AJ, Daniel SE, Kilford L, et al (1992) Accuracy of diagnosis of idiopathic Parkinson's disease: a clinicopathological study of 100 cases. J Neurol Neurosurg Psychiatry 55: 181-184
81. Hurwitz TA, Calne DB, Waterman K (1988) Treatment of dopaminomimetic psychosis in Parkinson's disease with electroconvulsive therapy. Can J Neurol Sci 15: 32-34
82. Idänpään-Heikkilä J, Alhava E, Olkinuora M, Palva I (1975) Clozapine and agranulocytosis. Lancet ii: 611
83. Ikeguchi K, Kuroda A (1995) Mianserin treatment of patients with psychosis induced by antiparkinsonian drugs. Eur Arch Psychiatry Clin Neurosci 244: 320-324
84. Iversen LL (1993) The D4 and schizophrenia. Nature 365: 393
85. Jankovic J, McDermott M, Carter J, et al (1990) Variable expression of Parkinson's disease: a base-line analysis of the DATATOP cohort. Neurology 40: 1529-1534
86. Jansen PAJ (1987) The development of new antipsychotic drugs: towards a new strategy in the management of chronic psychoses. J Drug Ther Res 12: 324-328
87. Jansen Steur ENH (1993) Increase of Parkinson disability after fluoxetine medication. Neurology 43: 211-213
88. Jansen ENH (1994) Clozapine in the treatment of tremor in Parkinson's disease. Acta Neurol Scand 89: 262-265
89. Javoy-Agid F, Taquet H, Ploska A, et al (1981) Distribution of catecholamines in the ventral mesencephalon of the human brain, with special reference to Parkinson's disease. J Neurochem 36: 2101-2105
90. Jiménez-Jiménez FJ, Tejeiro J, Martínez-Junquera G, et al (1994) Parkinsonism exacerbated by paroxetine. Neurology 44: 2406
91. Juul-Povlsen U, Noring U, Fog R, Gerlach J (1985) Tolerability and therapeutic effect of clozapine: a retrospective investigation of 216 patients, treated with clozapine for up to 12 years. Acta Psychiatr Scand 71: 176-185
92. Kafi S, Gaillard J (1976) Brain dopamine receptors and sleep in the rat: effects of stimulation and blockade. Eur J Pharmacol 38: 357-363
93. Karper LP, Salloway SP, Seibyl JP, Krystal JH (1992) Prolonged post-ictal encephalopathy in two patients with clozapine induced seizures. J Neuropsychiatry Clin Neurosci 4: 454-457
94. Kazee AM, Han LY (1995) Cortical Lewy bodies in Alzheimer's disease. Arch Path Lab Med 119: 448-453
95. Kieburtz K, McDermott M, Como P, et al (1994) The effect of deprenyl and tocopherol on cognitive performance in early untreated Parkinson's disease. Neurology 44: 1756-1759
96. Klawans HL (1988) Psychiatric side-effects during the treatment of Parkinson's disease. J Neural Transm 27 [Suppl]: 117-122
97. Koller WC (1984) Disturbance of recent memory function in parkinsonian patients on anticholinergic therapy. Cortex 20: 307-311
98. Krupp P, Barnes P (1992) Clozapine-associated agranulocytosis: risk and aetiology. Br J Psychiatry 160 [Suppl 17]: 38-40
99. Lang AE, Johnson K (1987) Akathisia in idiopathic Parkinson's disease. Neurology 37: 477-481
100. Lang AE, Sandor P, Duff J (1993) Remoxipride in Parkinson's disease: differential response in patients with dyskinesias/fiuctuations vs. psychosis. Ann Neurol 34: 301-302 (Abstract)
101. Launer M (1992) Diarrhoea during treatment with clozapine. Br Med J 305: 1160
102. Levin BE, Llabre MM, Reisman S (1991) A retrospective analysis of the effects of anticholinergic medication on memory performance in Parkinson's disease. J Neuropsychiatry Clin Neurosci 3: 412-416
103. Lew MF, Waters CH (1993) Clozapine treatment of parkinsonism with psychosis. J Am Geriatr Soc 41: 669-671
104. Lipinski JF Jr, Mallya G, Zimmerman, Pope HG Jr (1989) Fluoxetine-induced akathisia: clinical and theoretical implications. J Clin Psychiatry 50: 339-342
105. Lipper S (1976) Psychosis in patients on bromocriptine and levodopa with carbidopa. Lancet ii: 571-572
106. Litvan I, Mohr E, Williams J, Fedio P, Chase TN (1991) Differential memory and executive functions in demented patients with Parkinson's and Alzheimer's disease. J Neurol Neurosurg Psychiatry 54: 25-29
107. Livingston MG (1994) Risperidone. Lancet 343: 457-460
108. Lozano AM, Lang AE, Gálvez-Jiménez N, et al (1995) Effect of GPi pallidotomy on motor function in Parkinson's disease. Lancet 346: 1383-1387
109. Marsden CD, Parkes JD, Quinn N (1982) Fluctuations of disability in Parkinson's disease: clinical aspects. In: Marsden CD, Fahn S (eds) Movement disorders. Butterworth Scientific, London, pp 96-122
110. Martí MJ, Tolosa E (1991) Demencia en la enfermedad de Parkinson y en la enfermedad de Alzheimer: similitudes y diferencias. In: Esquerda JE, Gallego R, Gual A, Ramírez G, Rubia F (eds) Neurotransmisión y plasticidad sináptica. Espaxs, Barcelona, pp 293-309
111. Mayberg HS, Solomon DH (1995) Depression in Parkinson's disease: a biochemical and organic viewpoint. In: Weiner WJ, Lang AE (eds) Advances in neurology, vol 65. Behavioral neurology of movement disorders. Raven Press, New York, pp 49-60
112. Mayberg HS, Starkstein SE, Sadzot B, et al (1990) Selective hypometabolism in the inferior frontal lobe in depressed patients with Parkinson's disease. Ann Neurol 28: 57-64
113. Mayeux R, Stern Y, Rosen J, Leventhal J (1981) Depression, intellectual impairment, and Parkinson's disease. Neurology 31: 645-650
114. Mayeux R, Stern Y, Cote L, Williams JBW (1984) Altered serotonin metabolism in depressed patients with Parkinson's disease. Neurology 34: 642-646
115. Mayeux R, Stern Y, Williams JBW, et al (1986) Clinical and biochemical features of depression in Parkinson's disease. Am J Psychiatry 143: 756-759
116. Mayeux R, Denaro J, Hemenegildo N, Marder K, Tang M-X, Cote LJ, Stern Y (1992) A population-based investigation of Parkinson's disease with and without dementia. Arch Neurol 49: 492-497
117. McCance-Katz EF, Marek KL, Price LH (1992) Serotonergic dysfunction in depression associated with Parkinson's disease. Neurology 42: 1813-1814
118. McDermott HP, Jankovic J, Parkinson Study Group (1992) Factors predictive of the need for levodopa therapy in early, untreated Parkinson's disease. Neurology 42 [Suppl 3]: 441
119. Meco G, Alessandria A, Binfati V, Giustini P (1994) Risperidone for hallucinations in levodopa-treated Parkinson's disease patients. Lancet 343: 1370-1371
120. Megens AAHP, Awouters FHL, Schotte A, et al (1994) Survey on the pharmacodynamics of the new antipsychotic risperidone. Psychopharmacol 114: 9-23
121. Meier MJ, Martin WE (1970) Intellectual changes associated with levodopa therapy. JAMA 213: 456-466
122. Melamed E, Zoldan J, Friedberg G, Goldberg-Stein H (1993) Is hallucinosis in Parkinson's disease due to central serotonergic hyperactivity? Mov Disord 8: 406-407
123. Meltzer HY (1993) New drugs for the treatment of schizophrenia. Psychiatr Clin North Am 16: 365-385
124. Meltzer HY, Koenig JL, Nash JF, Gudelsky GA (1989a) Melperone and clozapine: neuroendocrine effects of typical neuroleptic drugs. Acta Psychiatr Scand 352 [Suppl]: 24-29
125. Meltzer HY, Matsubara S, Lee J-C (1989b) Classification of typical and atypical antipsychotic drugs on the basis of dopamine D1, D2 and serotonin-2 pKi values. J Pharmacol Exp Ther 251: 238-246
126. Meltzer HY, Kennedy J, Dai J, Parsa M, Riley D (1995) Plasma clozapine levels and the treatment of L-DOPA-induced psychosis in Parkinson's disease. A high potency effect of clozapine. Neuropsychopharmacol 12: 39-45
127. Mendis T, Mohr E, George A, et al (1994) Symptomatic relief from treatment-induced psychosis in Parkinson's disease: an open-label pilot study with remoxipride. Mov Disord 9: 197-200
128. Mindham RHS (1970) Psychiatric symptoms in parkinsonism. J Neurol Neurosurg Psychiatry 33: 181-191
129. Mohr E, Mendis T, Grimes DJ (1995) Late cognitive changes in Parkinson's disease with emphasis on dementia. In: Weiner WJ, Lang AE (eds) Advances in neurology, vol 65. Behavioral neurology of movement disorders. Raven Press, New York, pp 97-113
130. Molinari SP, Kaminski R, Di Rocco A, Yahr MD (1995) The use of famotidine in the treatment of Parkinson's disease: a pilot study. J Neural Transm [P-D Sect] 9: 243-247
131. Montastruc JL, Fabre N, Blin O, et al (1994) Does fluoxetine aggravate Parkinson's disease? A pilot prospective trial. Mov Disord 9 [Suppl 1]: 99
132. Moore NA, Axton MS (1988) Production of climbing behaviour in mice requires both D1 and D2 receptor activation. Psychopharmacol 94: 263-266
133. Moore NA, Tye NC, Axton MS, Risius FC (1992) The behavioural pharmacology of olanzapine, a novel "atypical" antipsychotic agent. J Pharmacol Exp Ther 262: 545-551
134. Moore S, Kenyon P (1994) Atypical antipsychotics, clozapine and sulpiride do not antagonise amphetamine-induced stereotyped locomotion. Psychopharmacol 114: 123-130
135. Moskovitz C, Moses H, Klawans H (1978) Levodopa induced psychosis: a kindling phenomena. Am J Psychiatry 135: 6-10
136. Müller T, Becker T, Fritze J (1988) Neuroleptic malignant syndrome after clozapine plus carbamacepine. Lancet ii: 1500
137. Naber D, Holzbach R, Perro C, Hippius H (1992) Clinical management of clozapine patients in relation to efficacy and side-effects. Br J Psychiatry 160 [Suppl 17]: 54-59
138. Narabayashi H (1996) Does stereotactic treatment of Parkinson's disease slow the progression of the disease? In: Battistin L, Scarlato G, Caraceni T, Ruggieri S (eds) Advances in neurology, vol 69. Parkinson's disease. Lippincot-Raven, Philadelphia, pp 557-562
139. Nausieda PA (1992) Sleep in Parkinson's disease. In: Koller WC (ed) Handbook of Parkinson's disease. Marcel Dekker, New York, pp 451-467
140. Nausieda PA, Weiner WJ, Kaplan LR, Weber S, Klawans HL (1982) Sleep disruption in the course of chronic levodopa therapy: an early feature of the levodopa psychosis. Clin Neuropharmacol 5: 183-194
141. Nausieda P, Tanner C, Klawans H (1983) Serotonergically active agents in the treatment of the levodopa induced psychosis. In: Fahn S, Calne DB, Shoulson I (eds) Advances in neurology, vol 37. Experimental therapeutics of movement disorders. Raven Press, New York, pp 23-32
142. Nausieda PA, Leo GJ, Chesney D (1994) Comparison of conventional and Sinemet CR on the sleep of parkinsonian patients. Neurology 44 [Suppl 2]: A219
143. Nutt JG, Gancher ST, Woodward WR (1988) Does inhibitory action of levodopa contribute to motor fluctuations? Neurology 38: 1553-1557
144. Ostergaard K, Dupond E (1988) Clozapine treatment of drug-induced psychotic symptoms in late stages of Parkinson's disease. Acta Neurol Scand 78: 349-350
145. Palazzini E, Soliveri P, Filippini G, et al (1995) Progression of motor and cognitive impairment in Parkinson's disease. J Neurol 242: 535-540
146. Parkinson J (1817) An essay on the shaking palsy. Whittingham and Rowland for Sherwood, Neely, and Jones, London
147. Parkinson Study Group (1993) Effect of deprenyl and tocopherol on the progression of disability in early Parkinson's disease. N Engl J Med 328: 176-183
148. Pfeiffer RF, Kang J, Graber B, Hofman R, Wilson J (1990) Clozapine for psychosis in Parkinson's disease. Mov Disord 5: 239-242
149. Pilowski LS, Costa DC, Elli PJ, et al (1992) Clozapine, single photon emission tomography, and the D2 dopamine receptor blockade hypothesis of schizophrenia. Lancet 340: 199-202
150. Pirozzolo FJ, Swihart AA, Rey GJ, Mahurin R, Jankovic J (1993) Cognitive impairments associated with Parkinson's disease and other movement disorders. In: Jankovic J, Tolosa E (eds) Parkinson's disease and movement disorders. Williams & Wilkins, Baltimore, pp 493-510
151. Pope HG Jr, Cole JO, Choras PT, Fulwiler CE (1986) Apparent neuroleptic malignant syndrome with clozapine and lithium. J Nerv Ment Dis 174: 493-495
152. Rajput AH, Pahwa R, Pahwa P (1992) Mode of onset and prognosis in Parkinson's disease. Neurology 42 [Suppl 3]: 419
153. Richelson E, Nelson A (1984) Antagonism by neuroleptics of neurotransmitter receptors of normal human brain in vivo. Eur J Pharmacol 103: 197-204
154. Ring H, Bench CJ, Trimble MR, Brooks DJ, Frackowiak RS, Dolan RJ (1994) Depression in Parkinson's disease. Br J Psychiatry 165: 333-339
155. Rinne UK (1983) Problems associated with long term levodopa treatment of Parkinson's disease. Acta Neurol Scand 95: 19-26
156. Robinson RG (1988) Post-stroke depression and lesion location. Stroke 19: 125
157. Rubinstein M, Gershanik OS, Stefano FJE (1988) Different roles of D1 and D2 dopamine receptors involved in locomotor activity in supersensitive mice. Eur J Pharmacol 148: 419-426
158. Rupniak NMJ, Hall MD, Mann S, et al (1985) Chronic treatment of clozapine, unlike haloperidol, does not induce changes in D-2 receptor function in the rat. Biochem Pharmacol 34: 2755-2763
159. Sadeh MS, Braham J, Modan M (1982) Effects of anticholinergic drugs on memory in Parkinson's disease. Arch Neurol 39: 666-667
160. Sano M, Stern Y, Marder K, Mayeux R (1990) A controlled trial of piracetam in intellectually impaired patients with Parkinson's disease. Mov Disord 5: 230-234
161. Santamaria J, Tolosa E (1992) Clinical subtypes of Parkinson's disease and depression. In: Huber SG, Cummings JL (eds) Parkinson's disease. Neurobehavioral aspects. Oxford University Press, New York, pp 217-228
162. Santamaria J, Tolosa E, Vallés A (1986) Parkinson's disease with depression: a possible subgroup of idiopathic parkinsonism. Neurology 36: 1130-1133
163. Scharf B, Moskowitz C, Moses H, Luptom M, Klawans H (1978) Dream phenomena induced by chronic levodopa therapy. J Neural Transm 43: 143-151
164. Scholz E, Dichgans J (1985) Treatment of drug-induced exogenous psychosis in parkinsonism with clozapine and fluperlapine. Eur Arch Psychiatry 235: 60-64
165. Seeman P (1992) Dopamine receptor sequences, therapeutic levels of neuroleptics occupy D2 receptors, clozapine occupies D4. Neuropsychopharmacol 7: 261-284
166. Seeman P, Guan HC, Van Tol HHM (1993) Dopamine D4 receptors elevated in schizophrenia. Nature 365: 441-445
167. Shaikh S, Coller D, Kerwin RW, et al (1993) Dopamine D4 receptor subtypes and response to clozapine. Lancet 341: 116
168. Shaw KM, Lees AJ, Stern GM (1980) The impact of treatment with levodopa on Parkinson's disease. Q J Med 49: 283-293
169. Sibley DR, Monsma FJ (1992) Molecular biology of dopamine receptors. TIPS 13: 61-69
170. Simpson GM, Cooper TA (1978) Clozapine plasma levels and convulsions. Am J Psychiatry 135: 99-100
171. Spencer DD, Robbins RJ, Naftolin F, et al (1992) Unilateral transplantation of human fetal mesencephalic tissue into the caudate nucleus of patients with Parkinson's disease. N Engl J Med 327: 1541-1548
172. Starkstein SE, Preziosi TJ, Berthier ML, et al (1989) Depression and cognitive impairment in Parkinson's disease. Brain 112: 1141-1153
173. Starkstein SE, Bolduc PL, Mayberg HS, Preziosi TJ, Robinson RG (1990) Cognitive impairment and depression in Parkinson's disease: a follow-up study. J Neurol Neurosurg Psychiatry 53: 597-602
174. Stern Y, Marder K, Tang MX, Mayeux R (1993) Antecedent clinical features associated with dementia in Parkinson's disease. Neurology 50: 1192-1196
175. Stein MB, Heuser IJ, Juncos JL, Uhde TW (1990) Anxiety disorders in patients with Parkinson's disease. Am J Psychiatry 147: 217-220
176. Tasker RR, DeCarvalho GC, Li CS, Kestle JRW (1996) Does thalamotomy alter the course of Parkinson's disease? In: Battistin L, Scarlato G, Caraceni T, Ruggieri S (eds) Advances in neurology, vol 69. Parkinson's disease. Lippincot-Raven, Philadelphia, pp 563-584
177. Thomas DR, Nelson DR, Johnson AM (1987) Biochemical effects of the antidepressant paroxetine, a specific 5-hydroxytryptamine uptake inhibitor. Psychopharmacology (Berlin) 93: 193-200
178. Thomas P, Goudeman M (1992) Seizures with low doses of clozapine. Am J Psychiatry 149: 138-139
179. Tison F, Dartigues JF, Auriacombe S, Letenneur L, Boller F, Alpérovitcj A (1995) Dementia in Parkinson's disease: a population-based study in ambulatory and instutionalized individuals. Neurology 45: 705-708
180. Tolosa E, Valldeoriola F, Martí MJ (1994) New and emerging strategies for improving levodopa treatment. Neurology 44 [Suppl 6]: 35-44
181. Tröster AI, Paolo AM, Lyons KE, Glatt SL, Hubble JP, Koller WC (1995) The influence of depression on cognition in Parkinson's disease: a pattern of impairment distinguishable from Alzheimer's disease. Neurology 45: 672-676
182. Van Beijsterveldt LEC, Geerts RJF, Leysen JE, et al (1994) Regional brain distribution of risperidone and its active metabolite 9-hydroxy-risperidone in the rat. Psychopharmacol 114: 53-62
183. Van Herwaarden G, Berger HJC, Horstink MWIM (1993) Short-term memory in Parkinson's disease after withdrawel of long-term anticholinergic therapy. Clin Neuropharmacol 16: 438-443
184. Van Tol HHM, Bunzow JR, Guan HC, et al (1991) Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature 350: 610-619
185. Walker JM, Matsumoto RR, Bowen WD, Gans DL, Jones KD, Walker FO (1988) Evidence for a role of haloperidol-sensitive sigma "opiate" receptors in the motor effects of antipsychotic drugs. Neurology 38: 961-965
186. Waters CH (1994) Fluoxetine and selegiline: lack of significant interaction. Can J Neurol Sci 21: 259-261
187. White A, Corn TH, Feetham, Faulconbridge C (1991) Ondansetron in treatment of schizophrenia. Lancet 337: 1173
188. Wiesel FA, Nordström AL, Farde L, Eriksson B (1994) An open clinical and biochemical study of ritanserin in acute patients with schizophrenia. Psychopharmacol 114: 31-38
189. Wilson JA, Smith RG (1989) The prevalence and aetiology of long term L-dopa side-effects in elderly parkinsonian patients. Age Ageing 18: 11-16
190. Wolters EC, Hurwitz TA, Mak E, et al (1990) Clozapine in the treatment of parkinsonian patients with dopaminomimetic psychosis. Neurology 40: 832-834
191. Yahr MD, Duvoisin RS, Schear MJ, Barrett RE, Hoehn MM (1969) Treatment of parkinsonism with levodopa. Arch Neurol 21: 343-354
192. Yaryura-Tobias JA, Diamond B, Merlis S (1970) Psychiatric manifestations of levodopa. Dis Nerv Syst 31: 60-63
193. Zoldan J, Friedberg G, Goldberg-Stern, Melamed E (1993) Ondansentron for hallucinosis in advanced Parkinson's disease. Lancet 341: 562-563
194. Zoldan J, Friedberg G, Weizman A, Melamed E (1996) Ondansetron, a 5-HT3 antagonist for visual hallucinations and paranoid delusional disorder associated with chronic L-DOPA therapy in advanced Parkinson's disease. In: Battistin L, Scarlato G, Caraceni T, Ruggieri S (eds) Advances in neurology, vol 69. Parkinson's disease. Lippincott-Raven, Philadelphia, pp 541-544